双联抗血小板治疗改善糖尿病合并严重肢体缺血患者股腘动脉支架置入结局
基于瑞典全国登记数据库的回顾性队列分析纳入1941例接受股腘动脉腔内介入的严重肢体缺血患者,其中599例(31%)术后接受双联抗血小板治疗(DAPT,阿司匹林联合氯吡格雷),1342例(69%)仅用阿司匹林。支架置入后接受DAPT者截肢率低于单用阿司匹林者(HR 0.56;95%CI 0.36-0.86),该保护作用在合并糖尿病的支架患者中最为明显(HR 0.26;95%CI 0.13-0.52;p<.001),且DAPT未增加出血并发症。
要点
- 股腘动脉支架置入后DAPT与截肢率降低相关(HR 0.56;95%CI 0.36-0.86)。
- DAPT的保肢获益主要见于合并糖尿病的支架置入患者(HR 0.26;95%CI 0.13-0.52;p<.001)。
- PTA或SAP后DAPT未影响保肢,DAPT与阿司匹林出血并发症无显著差异。
核心结论
- 在因严重肢体缺血行股腘动脉腔内介入的患者中,阿司匹林联合氯吡格雷的DAPT相比单用阿司匹林与更低的截肢率相关,且未增加出血率。
- DAPT对截肢的保护作用似乎局限于接受支架置入的糖尿病患者。
研究设计与样本
- 这是一项基于人群的回顾性全国队列分析,链接瑞典国家血管登记、处方药登记和国家出院登记数据库。
- 共识别1941例2006至2012年间因严重肢体缺血接受初次股腘动脉腔内介入的患者,中位年龄79岁(范围43-103岁),女性占58%。
- 599例(31%)术后接受DAPT(阿司匹林联合氯吡格雷),1342例(69%)仅用阿司匹林;PTA 1131例(58%)、支架置入633例(33%)、内膜下血管成形术(SAP)177例(9%)。
主要发现
- DAPT在PTA、支架置入和SAP后分别给予17%(n=188)、53%(n=334)和44%(n=77)的患者。
- 研究期间DAPT组77例(13%)、阿司匹林组228例(17%)发生大截肢。
- 支架置入后接受DAPT者截肢率低于单用阿司匹林者(HR 0.56;95%CI 0.36-0.86)。
- 亚组分析中DAPT的截肢保护作用似乎仅限于接受支架置入的糖尿病患者(HR 0.26;95%CI 0.13-0.52;p<.001)。
- PTA或SAP后DAPT未影响保肢,总体死亡率无差异,DAPT与阿司匹林出血并发症无显著差异。
临床怎么用
- 对因严重肢体缺血行股腘动脉支架置入的糖尿病患者,可考虑阿司匹林联合氯吡格雷的DAPT以降低截肢风险。
- PTA或SAP后使用DAPT未见保肢获益,决策时应结合出血风险评估个体化选择。
局限性
- 本研究为回顾性队列分析,非随机对照设计,存在选择偏倚可能。
- DAPT的获益主要来自亚组分析,需进一步前瞻性研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The purpose of this study was to analyse the effect of dual antiplatelet therapy (DAPT) compared to aspirin on outcome after endovascular interventions in patients with CLI. METHODS: This was a population based retrospective nationwide cohort analysis. Several linked national databases in Sweden: Swedish National Vascular Registry, Prescribed Drug Registry and National Discharge Registry. A total of 1941 patients (median age 79; range 43-103 years; women 58%) were identified with CLI who had undergone primary femoropopliteal endovascular intervention between 2006 and 2012. Of these, 599 (31%) patients were treated after the intervention with DAPT (aspirin and clopidogrel) and 1342 (69%) patients were treated with aspirin only. Percutaneous transluminal angioplasty (PTA) was performed in 1131 patients (58%), stenting in 633 patients (33%), and subintimal angioplasty (SAP) in 177 patients (9%). RESULTS: DAPT was given after PTA, stenting, and SAP to 17% (n = 188), 53% (n = 334), and 44% (n = 77) of the patients, respectively. During the study period, 77 patients (13%) with DAPT and 228 patients (17%) with aspirin underwent a major amputation. Patients receiving DAPT after stenting had a lower rate of amputation (HR 0.56; 95% CI 0.36-0.86) than patients receiving aspirin alone. In the subgroup analysis, the protective effect of DAPT on amputation seemed to be confined to patients with diabetes mellitus receiving a stent (HR 0.26; 95% CI 0.13-0.52; p < .001). DAPT after PTA or SAP did not influence limb salvage, and there was no overall difference in mortality. There was no significant difference in bleeding complications between DAPT and aspirin. CONCLUSION: DAPT with aspirin and clopidogrel compared to aspirin alone was associated with a lower amputation rate but not a higher bleeding rate in patients with diabetes and CLI after endovascular femoropopliteal stenting.
引用
- Thott O, Granath F, Malmstedt J, et al. Editor's Choice - Dual Antiplatelet Therapy Improves Outcome in Diabetic Patients Undergoing Endovascular Femoropopliteal Stenting for Critical Limb Ischaemia. Eur J Vasc Endovasc Surg. 2017. PMID: 28131536. doi:10.1016/j.ejvs.2016.12.014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。